NASDAQ:CWBR - CohBar Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.50
  • Forecasted Upside: 1,223.45 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.19
▲ +0.0089 (4.94%)

This chart shows the closing price for CWBR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CohBar Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CWBR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CWBR

Analyst Price Target is $2.50
▲ +1,223.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for CohBar in the last 3 months. The average price target is $2.50, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,223.45% upside from the last price of $0.19.

This chart shows the closing price for CWBR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in CohBar. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2021Cantor FitzgeraldInitiated CoverageOverweight$2.50High
4/23/2021Maxim GroupInitiated CoverageBuy$3.00High
3/31/2021AegisReiterated RatingBuyHigh
3/31/2021Chardan CapitalBoost Price TargetBuy$3.00 ➝ $3.50High
3/15/2021AegisInitiated CoverageBuy$6.00High
12/23/2020Chardan CapitalReiterated RatingBuyN/A
12/17/2020Chardan CapitalInitiated CoverageBuy$3.00High
11/10/2020Roth CapitalReiterated RatingMarket Perform ➝ Buy$8.00High
10/15/2020WBB SecuritiesInitiated CoverageBuy$4.50High
9/17/2020Roth CapitalReiterated RatingBuy$8.00Low
9/17/2020Roth CapitalInitiated CoverageBuy$8.00Low
5/28/2020Brookline Capital ManagementInitiated CoverageBuyN/A
5/27/2020Brookline Capital ManagementReiterated RatingBuyMedium
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 5 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/26/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2022
  • 1 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 1 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
CohBar logo
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $0.19
Low: $0.18
High: $0.19

50 Day Range

MA: $0.26
Low: $0.18
High: $0.34

52 Week Range

Now: $0.19
Low: $0.17
High: $2.27

Volume

9,183 shs

Average Volume

543,424 shs

Market Capitalization

$16.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.5

Frequently Asked Questions

What sell-side analysts currently cover shares of CohBar?

The following Wall Street analysts have issued research reports on CohBar in the last twelve months: Cantor Fitzgerald, and Zacks Investment Research.
View the latest analyst ratings for CWBR.

What is the current price target for CohBar?

0 Wall Street analysts have set twelve-month price targets for CohBar in the last year. Their average twelve-month price target is $2.50, suggesting a possible upside of 1,317.2%.
View the latest price targets for CWBR.

What is the current consensus analyst rating for CohBar?

CohBar currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CWBR will outperform the market and that investors should add to their positions of CohBar.
View the latest ratings for CWBR.

How do I contact CohBar's investor relations team?

CohBar's physical mailing address is 1455 Adams Drive Suite 2050, Menlo Park CA, 94025. The company's listed phone number is (650) 446-7888 and its investor relations email address is [email protected] The official website for CohBar is www.cohbar.com. Learn More about contacing CohBar investor relations.